SpyBiotech has concluded subject enrolment in its Phase I clinical trial of SPYVLP01, a vaccine candidate aimed at human cytomegalovirus (HCMV).
The vaccine leverages the company’s Hepatitis B virus-like particle platform to target HCMV.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe trial aims to evaluate the safety and immunogenicity of two different doses of the HCMV vaccine.
It enrolled 120 healthy adults aged 18-50 years over a six-month dosing schedule in the UK.
The company stated that an approved vaccine for HCMV does not currently exist.
HCMV, a betaherpesvirus causing lifelong infection, is claimed to have a prevalence rate of 55%-100%, depending on socio-economic and geographical factors.
SpyBiotech focuses on using new vaccine platform technologies to address infectious diseases, cancer, and chronic conditions.
Established in 2017 as a spinout from the University of Oxford by Oxford Science Enterprises (OSE) and Google Ventures (GV), the company secured $32.5m in Series A equity financing in 2021.
Its vaccine platform is based on protein ‘superglue’ technology, which enhances the binding of antigens to vaccine delivery platforms, thereby minimising delivery risk and improving immunogenicity and efficacy.
This technology is claimed to be well-suited for combating infectious diseases in challenging environments and has potential applications in cancer treatment.
SpyBiotech holds sole rights from the University of Oxford to apply, commercialise, and sub-license the SpyTag/SpyCatcher and associated ‘superglue’ technologies for vaccine development.
SpyBiotech CEO Mark Leuchtenberger said: “The end of enrollment in our Phase I trial of SPYVLP01 and the initial promising results both serve as a springboard as we move into the next phase of company development.
“We will continue to progress our scientific pipeline with a focus on our lead candidate and on our EBV-focused collaboration with the University of Oxford.”
